ABOUT Benjamin Tsai

Mr. Tsai is a Partner at Invus Opportunities, a NY-based investment firm with approximately $2 billion under management, where he has led numerous growth investments in healthcare and technology companies since 2008 and served on the Board of over twenty companies as a Director or Board Observer. Representative life sciences investments that have been acquired or gone public include Auris (sold to J&J), Aquesys and Kythera (both sold to Allergan), CardiAQ and Valtech Cardio (both sold to Edwards Lifesciences), Novocure (NASDAQ:NVCR), ORIC (NASDAQ:ORIC), Oyster Point (NASDAQ:OYST), Rebound Medical (acquired by Integra).

Ben is also an active investor in growth-stage software and fintech companies and sits on the Investment Committee of Invus Opportunities.  Previously, Ben was a management consultant at the Monitor Group, where he advised senior executives of companies globally on their most critical strategic issues, including market-leading biotechnology and medical device companies. He holds an MBA degree from Harvard Business School and a BS degree from the University of Southern California, where he was a Trustee Scholar and member of the Baccalaureate/MD program.